Vectus Completes VB4-P5 Sale Receiving 154,544 Shares and 692,150 Warrants

VB4-P5 Sale Secures Strategic Equity Stake

Vectus Biosystems (ASX:VBS) has transformed its VB4-P5 renal fibrosis asset into a near 10% ownership position in Canadian biotech XORTX Therapeutics. The deal closed on 14 April 2026, with XORTX issuing 154,544 common shares; representing 9.9% of its issued capital; and 692,150 pre-funded warrants to Vectus. This equity stake aligns with Vectus’ strategy to advance early drug candidates to commercial attractiveness before partnering or divesting. The transaction means Vectus retains a vested interest in VB4-P5’s development without further financial outlay, as XORTX assumes responsibility for its progression. The company has also agreed to lockup periods on portions of these securities ranging from 45 to 180 days post-closing.

This milestone builds on the binding term sheet announced in October 2025 and finalises a deal valued at several million dollars in equity and warrants, a move that was anticipated in earlier quarters during a period of cost rationalisation and pipeline focus. The sale provides Vectus with a foothold in a Nasdaq and TSX-listed entity, potentially opening new avenues for collaboration or liquidity events once lockup restrictions ease. The company’s broader drug library, including VB0004, VB4-A32, and VB4-A79, remains under active commercialisation efforts.

Licensing Drive Continues Amid Pipeline Focus

While the VB4-P5 sale marks a significant capital event, Vectus’ core activity remains the licensing and commercialisation of its lead compound VB0004, alongside emerging candidates targeting liver and lung fibrosis. The company, in partnership with C14 Consulting Group, is actively engaging pharmaceutical industry players, providing data room access to interested parties to facilitate potential licence agreements or transactions. This outreach forms a critical part of Vectus’ strategy to monetise its portfolio without heavy ongoing R&D expenditure.

Fibrosis remains a major unmet medical need globally, and Vectus’ orally doseable small molecules aim to address this with patent-protected compounds designed for cardiovascular organ targets. The company’s recent Phase Ia/Ib human clinical trials have concluded, and ongoing data compilation supports its commercial discussions. The commercialisation push follows a pattern of reduced operational outlays, with the company spending $130,000 in the March quarter primarily on commercialisation, intellectual property renewals, and corporate overheads.

Cash Position Tightens; Funding Strategies Under Review

Vectus ended the quarter with $94,000 in cash on hand, down from $330,000 at the end of the previous quarter, reflecting the winding down of clinical activities and ongoing commercialisation costs. The company has a $550,000 loan facility from director Maurie Stang, with $450,000 drawn, repayable without penalty upon securing alternative funding. With estimated available funding covering less than one quarter of operating costs at current burn rates, Vectus is actively exploring various capital options, including the potential monetisation of its XORTX shares once escrow periods expire.

These financial dynamics underscore the challenges biotech firms face in balancing pipeline development with limited cash reserves. Vectus’ approach to reduce overheads and seek licensing partners to fund further clinical studies reflects a pragmatic response to these pressures. The company expects to sustain operations through a combination of cost control, licensing revenue, and potential liquidity from its XORTX equity stake.

Notably, the sale of VB4-P5 and the ongoing licensing efforts continue a strategic pivot observed since late 2025, which saw Vectus cut losses and sharpen its focus on commercialisation, as documented in its earlier quarterly updates and near $4.3M XORTX deal and converts VB4-P5 asset. This trajectory highlights a company navigating the difficult transition from clinical development to commercial partnerships in the competitive fibrosis treatment space.